Navigation Links
Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
Date:9/12/2008

r of high quality institutional investors. The offering will allow us to accelerate the non-clinical development program we believe will be required for us to file an NDA for CPP-109, broaden our pilot study program and provide us with additional financial strength as we move forward with our business activities including ongoing discussions with potential strategic partners."

The securities described above are being offered by Catalyst pursuant to a previously filed shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on June 26, 2008. The shares of common stock may only be offered by means of a prospectus supplement and accompanying prospectus, forming a part of the effective shelf registration statement. Copies of the base prospectus and the prospectus supplement for the offering can be obtained from Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, New York, 10020, or by calling (212) 356-0549. An electronic copy of the prospectus and prospectus supplement will also be available on the website of the Securities and Exchange Commission at http://www.sec.gov.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the United States relating to the right to use vigabatrin to treat a w
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIST and partners identify tiny gold clusters as top-notch catalysts
2. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
3. Controlling the size of nanoclusters: First step in making new catalysts
4. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
5. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
6. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
7. Experiments reveal unexpected activity of fuel cell catalysts
8. Using catalysts to stamp nanopatterns without ink
9. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
10. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
11. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/27/2015)... PureTech , a science and technology R&D company focused  ... in the healthcare sector, announced today the appointment of ... the Board of Directors of Sanofi, to its Board ... pleasure to know Chris for many years and I ... more closely now," said Dr. Robert Langer , ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 423andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... it Possible for Employers to Hire Overseas Workers - ... Today,s outsourcing industry has taken a giant leap forward ... Systems ( http://www.cybracero.com ), which makes it possible ... the first-world countries without ever having to leave their ...
... for Samtheo,s Personalized Medicine PortfolioNEW YORK, March 16 ... license agreement, through its subsidiary, Lyndor Biosciences LLC, ... to a small molecule that selectively inhibits the ... activation of the Akt pathway has been found ...
... Call to be Held at 9:00 a.m. Eastern Time ... 16 United Therapeutics Corporation (Nasdaq: UTHR ... interactions with the U.S. Food and Drug Administration (FDA), ... Application (NDA) for Tyvaso(TM) (inhaled treprostinil) will likely extend ...
Cached Biology Technology:New Technology to Revolutionize the Way the Planet Does Business 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 2United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso) 3
(Date:2/5/2015)... , Jan. 28, 2015 Research and ... the addition of the "Global Biometrics Market ... Regions and Countries " report to their offering. ... Asia-Pacific is anticipated to ... 2015, owing to increasing government spending towards IT ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Elderly mice suffering from age-related heart disease saw a significant ... drug rapamycin for just three months. The research, led ... Research on Aging, shows how rapamycin impacts mammalian tissues, providing ... been shown to extend the lifespan of mice as much ...
... Scientists at Rice University and Oak Ridge National Laboratory ... a method to control the growth of uniform atomic layers ... of a trilogy of materials needed to make functioning 2-D ... manufacture of devices so small they would be invisible to ...
... part of the skeletal support for the membrane in ... Joanny from the Physico Chemistry Curie Unit at the ... a well-defined layer beneath the cell outer membrane forms ... motor proteins within the cellular system. These findings, which ...
Cached Biology News:Lifespan-extending drug given late in life reverses age-related heart disease in mice 22-D electronics take a step forward 22-D electronics take a step forward 3
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
...
Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
Biology Products: